On August 26, SBP GROUP rose 3.29% in regular trading, trading at 5.825 HKD/share, with turnover of approximately 190 million HKD.

On the news front, the company announced that CPX301, a GLP-1 receptor agonist dissolvable microneedle patch developed by its core subsidiary Beijing Tide Pharmaceutical, has received Investigational New Drug clearance from the US FDA for weight management. The product features convenient administration, efficient drug delivery, sterile safety, and ease of storage and transport, potentially offering a novel delivery option for patients requiring long-term weight management.

In addition, the company's subsidiary Chia Tai Tianqing recently obtained NMPA clinical trial approval for TQF6422 injection, a Class 1 innovative drug targeting weight management in adult patients with obesity or overweight with at least one weight-related comorbidity. The dual approvals reinforce the company's expanding pipeline in the competitive GLP-1 and obesity treatment space. The movement also comes on the heels of strong H1 results reported on August 19, with revenue reaching a record 19.44 billion RMB and adjusted net profit surging 92.3% year-over-year, prompting multiple analyst upgrades.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)